Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

Publications
Mar 2025
Sean Murray and Jeremiah Helm Discuss Strategies for Practitioners Facing Numerous Patent Claims in Law360 Column
In the latest installment of their series on recent noteworthy Federal Circuit decisions, partners Sean Murray and Jeremiah Helm discuss a case “that will make life harder for defendants accused...
Blog - IP Practice
Apr 2025
No Error: The Board Committed No Procedural Error by Relying on Evidence Outside of the Prior Art Reference
SAGE PRODUCTS, LLC v. STEWART [OPINION] Before Reyna, Cunningham, and Stark.  Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board. Summary: The Board did not...
Publications
Apr 2025
Jeremiah Helm and Sean Murray Discuss Forfeiting Claim Construction on Appeal in Law360 Column
In the latest installment of their Law360 column on recent noteworthy Federal Circuit decisions, partners Jeremiah Helm and Sean Murray examine the court’s ruling in Wash World Inc. v. Belanger...